Immunohistochemical analysis of bilateral breast carcinomas: tendency to concordance of ER, PgR and erbB2/HER2 status

被引：0
|
作者：
Suspitsin, E.
Giercksky, H.
Lazareva, Y.
Matsko, D.
Borresen-Dale, A.-L.
Imyanitov, E.
机构：
[1] NN Petrov Inst Oncol, Grp Mol Diagnost, St Petersburg, Russia
[2] Norwegian Radium Hosp, Oslo, Norway
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：81 / 81
页数：1
相关论文
共 50 条
  • [21] HER2/ERBB2 immunoreactivity in human retinoblastoma
    Seigel, G. M.
    Sharma, S.
    Hackam, A. S.
    Shah, Dhaval K.
    TUMOR BIOLOGY, 2016, 37 (05) : 6135 - 6142
  • [22] Clinical validation of the concordance performance of ERBB2 status by single-cells genomics ERBB2 (HER2) amplification Assay in Circulating Tumor Cells (CTCs) from patients with matched HER2 status from metastatic tissue biopsies
    Di Caro, Giuseppe
    Lam, Ernest
    Slade, Megan
    Huang, Shuguang
    Wenstrup, Rick
    Schwartzberg, Lee
    CANCER RESEARCH, 2024, 84 (09)
  • [23] The Mysterious Ways of ErbB2/HER2 Trafficking
    Bertelsen, Vibeke
    Stang, Espen
    MEMBRANES, 2014, 4 (03): : 424 - 446
  • [24] Dual ERBB2 (HER2) Gene Protein Assay: Focused Study of Breast Cancers with 2+Immunohistochemical Expression
    Li, Z.
    Dabbs, D. J.
    Bhargava, R.
    MODERN PATHOLOGY, 2014, 27 : 64A - 64A
  • [25] The prognostic value of microarray ERBB2 gene and immunohistochemical stain/FISH of HER2 for early breast cancer patients
    Chen, P. Y.
    Cheng, S. H. C.
    Yu, B. L.
    Chen, C. M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S303 - S303
  • [26] Dual ERBB2 (HER2) Gene Protein Assay: Focused Study of Breast Cancers with 2+Immunohistochemical Expression
    Li, Z.
    Dabbs, D. J.
    Bhargava, R.
    LABORATORY INVESTIGATION, 2014, 94 : 64A - 64A
  • [27] ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer
    David F. Stern
    Journal of Mammary Gland Biology and Neoplasia, 2008, 13
  • [28] Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
    Croessmann, Sarah
    Formisano, Luigi
    Kinch, Lisa N.
    Gonzalez-Ericsson, Paula I.
    Sudhan, Dhivya R.
    Nagy, Rebecca J.
    Mathew, Aju
    Bernicker, Eric H.
    Cristofanilli, Massimo
    He, Jie
    Cutler, Richard E., Jr.
    Lalani, Alshad S.
    Miller, Vincent A.
    Lanman, Richard B.
    Grishin, Nick V.
    Arteaga, Carlos L.
    CLINICAL CANCER RESEARCH, 2019, 25 (01) : 277 - 289
  • [29] Breast Cancer HER2 (ERBB2) Status by Next-Generation Sequencing Compared to Traditional Methods
    Russell, Meaghan K.
    Pantazi, Angeliki
    Lyle, Stephen
    Tse, Julie Y.
    LABORATORY INVESTIGATION, 2018, 98 : 103 - 103
  • [30] Breast Cancer HER2 (ERBB2) Status by Next-Generation Sequencing Compared to Traditional Methods
    Russell, Meaghan K.
    Pantazi, Angeliki
    Lyle, Stephen
    Tse, Julie Y.
    MODERN PATHOLOGY, 2018, 31 : 103 - 103
12345